Quinolones have long been used as the first-line treatment for
Campylobacter infections. However, an increased resistance to
quinolones has raised public health concerns. The development of new
quinolone-based
antibiotics with high activity is critical for effective, as
DNA gyrase, the target of
quinolones, is an essential
enzyme for bacterial growth in several mechanisms. The evaluation of
antibiotic activity against Campylobacter jejuni largely relies on
drug susceptibility tests, which require at least 2 days to produce results. Thus, an in vitro method for studying the activity of
quinolones against the C. jejuni
DNA gyrase is preferred. To identify potent
quinolones, we investigated the interaction of C. jejuni
DNA gyrase with a number of
quinolones using recombinant subunits. The combination of purified subunits exhibited
DNA supercoiling activity in an
ATP dependent manner.
Drug concentrations that inhibit
DNA supercoiling by 50% (IC50s) of 10 different
quinolones were estimated to range from 0.4 (
sitafloxacin) to >100 μg/mL (
nalidixic acid).
Sitafloxacin showed the highest inhibitory activity, and the analysis of the
quinolone structure-activity relationship demonstrated that a
fluorine atom at R-6 might play the important role in the inhibitory activity against C. jejuni gyrase. Measured
quinolone IC50s correlated well with minimum inhibitory concentrations (R = 0.9943). These suggest that the in vitro supercoiling inhibition assay on purified recombinant C. jejuni
DNA gyrase is a useful and predictive technique to monitor the antibacterial potency of
quinolones. And furthermore, these data suggested that
sitafloxacin might be a good candidate for clinical trials on
campylobacteriosis.